UNSPSC 51172202: Butaphosphan

This classification denotes a phosphorous supplement with the molecular formula C7H17NO2P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q2LQ1149L, chemically known as 2-(butylamino)propan-2-yl-hydroxy-oxophosphanium but generally known as casanthranol, which bears US NIH Compound Identifier 6328684. BUTAPHOSPHAN, as BUTAFOSFAN, is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

European Medicines Agency schedules Butaphosphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05997MIG. SMILES: CCCCNC(C)(C)[P+](=O)O.

UNSPSC 51172202 Butaphosphan is a Commodity code nominally designating an organophosphorus compound used as a veterinary pharmaceutical; however, recent state and local solicitation activity under this code does not reflect pharmaceutical or veterinary procurement aligned with the code's stated scope. The three most recent opportunities tagged to this code—specimen collection and drug testing services, a therapeutic pharmacy initiative direct-to-manufacturer RFI, and a multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products—are plainly unrelated to butaphosphan as a chemical input or finished veterinary product. The mismatch suggests either a data-tagging error in the state and local opportunities indexed under this code or a fundamental misalignment between the code's nominal definition and the jurisdictions' procurement classification practices.

With no recent opportunities directly aligned to butaphosphan procurement itself, the code shows little active market engagement among state and local buyers. Entities posting notices under this code include Collin County (Texas), the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance, but their work spans human drug testing administration, pharmacy benefit program design, and multi-jurisdictional pharmaceutical distribution—categories that do not correspond to butaphosphan supply or application. Geographic concentration is absent because the underlying procurement activity is not germane to the code. Firms evaluating this code for business development should verify classification with prospective buyers before pursuing opportunities, as the current indexing does not reflect a coherent, active market for butaphosphan itself in state and local government.